Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of TQA2225/AP025 in adults with nonalcoholic steatohepatitis
CTR20232280Phase 2Active
- Sponsor
- AnYuan Pharmaceutical
- Start
- Sep 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of TQA2225 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by AnYuan Pharmaceutical. Started Sep 2023; status: active.
02
Drugs
TQA2225
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20232280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232280.